Circio announces strengthened in vivo data and enhanced circVec 2.2 design, presented by management in R&D webcast
· circVec 2.1 DNA vectors have now demonstrated higher and more durable expression vs. conventional mRNA-based expression in vivo for up to five months · Machine learning sequence optimization has resulted in a new and enhanced circVec 2.2 design, which increases protein expression by 2-4 -fold vs. circVec 2.1 · The enhanced circVec expression durability can deliver substantial improvement over current gold-standard gene therapy approaches · Circio management presents and discusses these data in a webcast published today, 17 June 2024, watch the webcast here